The Effect of Ketamine on Attentiveness
Investigate the Effect of S-Ketamine, as Pharmacological Model of Schizophrenia, on the Attentiveness and Working Memory Simultaneously Measured With Functional Magnetic Resonance Imaging(fMRI)/Electroencephalogram(EEG)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Normal ECG and safety assessments, or minor no-relevant deviations, at screening
- Vital signs: systolic between 100 and 140 mmHg and diastolic between 50 and 90 mmHg and heart rate between 45 and 90 beats/min
- No medication intake in the last four weeks
- Volunteers must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and to adhere to the prohibitions and restrictions specified in the protocol
- Negative drug screen
Exclusion Criteria:
- Participation in another clinical trial in the last 3 months
- Significant allergies, allergic diathesis or known hypersensitivity for ketamine or its ingredients (ie, Benzethonium chloride)
- History of or current significant respiratory disease, cardiovascular disease, endocrinological, gastrointestinal, neurological, glaucoma and known liver and kidney failure
- Contraindications for an MRI being performed (claustrophobia, metal parts, pacemaker)
- oxygen saturation pO2 < 90 mmHg
- Clinically significant abnormalities in ECG or laboratory values
- Recent history (within previous 6 months) of alcohol or drug abuse
- History of or current psychiatric diagnoses (DSM-IV, II) or neurological disorders
- Relatives in first or second degree with a schizophrenic disorder
- Serology positive for hepatitis B surface antigen, hepatitis C antibodies or HIV antibodies
- Signs of hyperthyroidism based on the determination of T3, T4 and TSH
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 001
ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
|
An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
|
|
Experimental: 002
Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start.
Dosage lowered every 10 minutes
|
An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start.
Dosage lowered every 10 minutes
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cerebral activation of ketamine as determined by functional MRI
Time Frame: 25 and 40 minutes after end of bolus injection of ketamine/placebo
|
25 and 40 minutes after end of bolus injection of ketamine/placebo
|
|
Cerebral activation of ketamine as determined by electroencephalogram (EEG) during an oddball-task
Time Frame: 25 and 40 minutes after end of bolus injection of ketamine/placebo
|
25 and 40 minutes after end of bolus injection of ketamine/placebo
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect of Ketamine on consciousness as measured by the "Altered States of Consciousness Rating Scale"
Time Frame: 60 min after end of bolus injection of ketamine.
|
60 min after end of bolus injection of ketamine.
|
|
Cerebral activation induced by ketamine as measured by simultaneous fMRI / EEG under resting conditions
Time Frame: 0 and 25 min after end of bolus injection of ketamine.
|
0 and 25 min after end of bolus injection of ketamine.
|
|
Symptom score of ketamine as measured with the Positive And Negative Symptom Scale
Time Frame: 60 min after end of bolus injection of ketamine (= at the end of ketamine infusion).
|
60 min after end of bolus injection of ketamine (= at the end of ketamine infusion).
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
Other Study ID Numbers
- CR017368
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.